

MARRONE BIO INNOVATIONS INC  
 Form 3  
 August 01, 2013

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Pitts Keith (Last) (First) (Middle)  C/O MARRONE BIO INNOVATIONS, INC.,Â 2121 SECOND STREET, SUITE A-107 (Street)  DAVIS,Â CAÂ 95618 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2013	3. Issuer Name and Ticker or Trading Symbol MARRONE BIO INNOVATIONS INC [MBII]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) See Remarks	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	---	---	--	---

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â <u>(1)</u>	07/21/2018	Common Stock	15,931	\$ 0.47	D	Â
Stock Option (Right to Buy)	Â <u>(2)</u>	01/28/2019	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	Â <u>(3)</u>	01/11/2020	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	Â <u>(4)</u>	01/11/2020	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	01/24/2021	Common Stock	17,620	\$ 1.19	D	Â
Stock Option (Right to Buy)	Â <u>(6)</u>	12/15/2021	Common Stock	15,931	\$ 1.41	D	Â
Stock Option (Right to Buy)	Â <u>(7)</u>	02/20/2022	Common Stock	11,487	\$ 3.11	D	Â
Stock Option (Right to Buy)	Â <u>(8)</u>	10/18/2022	Common Stock	23,897	\$ 12.08	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Pitts Keith C/O MARRONE BIO INNOVATIONS, INC. 2121 SECOND STREET, SUITE A-107 DAVIS, CA 95618	Â	Â	Â See Remarks	Â

## Signatures

/s/ Donald J. Glidewell, Donald J. Glidewell,  
Attorney-in-Fact

08/01/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of July 1, 2008, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
  - (2) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2009, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
  - (3) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2010, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
  - (4) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2010.

## Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

- (5) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2011.
- (6) The options vest with respect to 1/60th of the total shares subject to the option one month after the vesting commencement date of November 1, 2011, and 1/60th of the total shares subject to the option monthly thereafter for 36 months.
- (7) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of February 20, 2012.
- (8) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of October 18, 2012, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.

Â

### **Remarks:**

ViceÂ PresidentÂ ofÂ RegulatoryÂ andÂ GovernmentalÂ Affairs

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.